Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience

2012 ◽  
Vol 14 (6) ◽  
pp. 471-480
Author(s):  
Robert Díaz Beveridge ◽  
Jorge Aparicio ◽  
Alejandro Tormo ◽  
Rafael Estevan ◽  
Josefina Artes ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Preoperative Chemoradiotherapy ◽  
Long Term Results ◽  
Single Institution ◽  
Oral Fluoropyrimidines ◽  
Resectable Rectal Cancer

Long-Term Oncologic Results and Complications After Preoperative Chemoradiotherapy for Rectal Cancer: A Single-Institution Experience After a Median Follow-Up of 95 Months

2009 ◽  
Vol 16 (4) ◽  
pp. 893-899 ◽  
Author(s):  
Salvatore Pucciarelli ◽  
Giuseppe Gagliardi ◽  
Isacco Maretto ◽  
Sara Lonardi ◽  
Maria Luisa Friso ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Preoperative Chemoradiotherapy ◽  
Single Institution ◽  
Oncologic Results

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study

2014 ◽  
Vol 15 (2) ◽  
pp. 184-190 ◽  
Author(s):  
Jean-François Bosset ◽  
Gilles Calais ◽  
Laurent Mineur ◽  
Philippe Maingon ◽  
Suzana Stojanovic-Rundic ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Preoperative Chemoradiotherapy ◽  
Long Term Results ◽  
Randomised Study

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

2019 ◽  
Vol 37 (33) ◽  
pp. 3111-3123 ◽  
Author(s):  
Yong Sang Hong ◽  
Sun Young Kim ◽  
Ji Sung Lee ◽  
Byung-Ho Nam ◽  
Kyu-pyo Kim ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Subgroup Analysis ◽  
Controlled Trial ◽  
Disease Free Survival ◽  
Preoperative Chemoradiotherapy ◽  
Hazard Ratio ◽  
Long Term Results ◽  
Intention To Treat

PURPOSE We evaluated the role of oxaliplatin as adjuvant chemotherapy in patients with rectal cancer who received preoperative chemoradiotherapy (CRT) with fluoropyrimidine monotherapy and total mesorectal excision (TME). METHODS The ADORE trial (adjuvant oxaliplatin in rectal cancer) is a multicenter, randomized trial in patients with postoperative ypStage II (ypT3-4N0) or III (ypTanyN1-2) rectal cancer after fluoropyrimidine-based preoperative CRT and TME. Patients were randomly assigned (1:1) to receive adjuvant chemotherapy either with FL (fluorouracil 380 mg/m2 and leucovorin 20 mg/m2) or FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil bolus 400 mg/m2 on day 1, fluorouracil infusion 2,400 mg/m2 for 46 hours). Stratification factors included ypStage and participating center. Primary end point was disease-free survival (DFS). RESULTS A total of 321 patients were enrolled between November 19, 2008, and June 12, 2012. Six-year DFS rates were 68.2% in the FOLFOX arm versus 56.8% in the FL arm, with a stratified hazard ratio of 0.63 (95% CI, 0.43 to 0.93; P = .018) by intention-to-treat analysis. In the subgroup analysis for DFS, FOLFOX was favorable versus FL in patients with ypStage III, ypN1b, ypN2, high-grade histology, minimally regressed tumor, and an absence of lymphovascular or perineural invasion. Six-year overall survival rate was 78.1% in the FOLFOX arm versus76.4% in the FL arm (hazard ratio, 0.73; 95% CI, 0.45 to 1.19; P = .21). In the subgroup analysis for OS, FOLFOX was favorable versus FL in patients with ypN2 and minimally regressed tumor. CONCLUSION Adjuvant FOLFOX improved DFS in patients with rectal cancer with ypStage II and III disease after preoperative CRT. Adjuvant FOLFOX may be considered on the basis of the postoperative pathologic stage in those who received preoperative CRT and TME.

Sign in / Sign up

Export Citation Format

Share Document